Vanda Shares Climb on Reiterated Cycle Acquisition Offer

Dow Jones

2024-10-14

By Dean Seal

Shares of Vanda Pharmaceuticals jumped after Cycle Pharmaceuticals reaffirmed its proposal to buy the company for $8 a share.

The stock was up 18% at $5.22 in early trading. Shares have gained 24% since the start of the year.

Cycle said Monday morning that it is still offering to buy Vanda for $8 a share in cash despite Vanda's board refusing to engage with Cycle and rejecting its proposal on Oct. 7.

"Vanda's board and management team … have continued to prioritize their own interests and self-preservation with egregious actions that blatantly disenfranchise Vanda shareholders," Cycle said.

Vanda rejected proposals from both Cycle and the company Future Pak earlier this year, calling each inadequate. In June, Future Pak formally withdrew its offer to buy the company for $8.50 to $9 a share.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

October 14, 2024 10:28 ET (14:28 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2475987893"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2475987893\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2475987893?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-14 22:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2475987893","market":"sg","top_or_hot":-1,"title":"Vanda Shares Climb on Reiterated Cycle Acquisition Offer","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n     By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Vanda Pharmaceuticals jumped after Cycle Pharmaceuticals reaffirmed its proposal to buy the company for $8 a share. \n</p>\n<p>\n  The stock was up 18% at $5.22 in early trading. Shares have gained 24% since the start of the year. \n</p>\n<p>\n  Cycle said Monday morning that it is still offering to buy Vanda for $8 a share in cash despite Vanda's board refusing to engage with Cycle and rejecting its proposal on Oct. 7. \n</p>\n<p>\n  \"Vanda's board and management team … have continued to prioritize their own interests and self-preservation with egregious actions that blatantly disenfranchise Vanda shareholders,\" Cycle said. \n</p>\n<p>\n  Vanda rejected proposals from both Cycle and the company Future Pak earlier this year, calling each inadequate. In June, Future Pak formally withdrew its offer to buy the company for $8.50 to $9 a share. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 14, 2024 10:28 ET (14:28 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vanda Shares Climb on Reiterated Cycle Acquisition Offer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVanda Shares Climb on Reiterated Cycle Acquisition Offer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-10-14 22:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n     By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of Vanda Pharmaceuticals jumped after Cycle Pharmaceuticals reaffirmed its proposal to buy the company for $8 a share. \n</p>\n<p>\n  The stock was up 18% at $5.22 in early trading. Shares have gained 24% since the start of the year. \n</p>\n<p>\n  Cycle said Monday morning that it is still offering to buy Vanda for $8 a share in cash despite Vanda's board refusing to engage with Cycle and rejecting its proposal on Oct. 7. \n</p>\n<p>\n  \"Vanda's board and management team … have continued to prioritize their own interests and self-preservation with egregious actions that blatantly disenfranchise Vanda shareholders,\" Cycle said. \n</p>\n<p>\n  Vanda rejected proposals from both Cycle and the company Future Pak earlier this year, calling each inadequate. In June, Future Pak formally withdrew its offer to buy the company for $8.50 to $9 a share. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean Seal at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 14, 2024 10:28 ET (14:28 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2475987893","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2475987893","pubTimestamp":1728916080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Vanda Pharmaceuticals jumped after Cycle Pharmaceuticals reaffirmed its proposal to buy the company for $8 a share.The stock was up 18% at $5.22 in early trading. Shares have gained 24% since the start of the year.Cycle said Monday morning that it is still offering to buy Vanda for $8 a share in cash despite Vanda's board refusing to engage with Cycle and rejecting its proposal on Oct. 7.have continued to prioritize their own interests and self-preservation with egregious actions that blatantly disenfranchise Vanda shareholders,\" Cycle said.Vanda rejected proposals from both Cycle and the company Future Pak earlier this year, calling each inadequate. In June, Future Pak formally withdrew its offer to buy the company for $8.50 to $9 a share.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VNDA":"万达生物制药"},"translate_title":"Vanda股价因重申周期收购要约而攀升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VNDA":0.9},"content_text":"By Dean Seal \n\n\n \n\n\n  Shares of Vanda Pharmaceuticals jumped after Cycle Pharmaceuticals reaffirmed its proposal to buy the company for $8 a share. \n\n\n  The stock was up 18% at $5.22 in early trading. Shares have gained 24% since the start of the year. \n\n\n  Cycle said Monday morning that it is still offering to buy Vanda for $8 a share in cash despite Vanda's board refusing to engage with Cycle and rejecting its proposal on Oct. 7. \n\n\n  \"Vanda's board and management team … have continued to prioritize their own interests and self-preservation with egregious actions that blatantly disenfranchise Vanda shareholders,\" Cycle said. \n\n\n  Vanda rejected proposals from both Cycle and the company Future Pak earlier this year, calling each inadequate. In June, Future Pak formally withdrew its offer to buy the company for $8.50 to $9 a share. \n\n\n \n\n\n  Write to Dean Seal at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 14, 2024 10:28 ET (14:28 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}